Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: The MONALISA study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 117, Issue 12, 2010, Pages 1475-1484

  Judlin, P ^a   Liao, Q ^b   Liu, Z ^b   Reimnitz, P ^c   Hampel, B ^d   Arvis, P ^e  

^a Maternite Regionale Universitaire   (France)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c BAYER AG   (Germany)

^d BAYER PHARMA AG   (Germany)

^e NONE   (France)

Author keywords

Levofloxacin; metronidazole; moxifloxacin; uncomplicated pelvic inflammatory disease

Indexed keywords

CEFTRIAXONE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL EVALUATION; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GONORRHEA; HUMAN; INSOMNIA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; STOMACH DISCOMFORT; STREPTOCOCCUS AGALACTIAE; TREATMENT DURATION; TREATMENT OUTCOME; UNCOMPLICATED PELVIC INFLAMMATORY DISEASE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; PELVIC INFLAMMATORY DISEASE; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349249474     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02687.x     Document Type: Article

References (46)

1. Simms I, Rogers P, Charlett A,. The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales. Int J STD AIDS 1999; 10: 448 - 51.
2. National Survey of Family Growth; Vital and Health Statistics. Hyattsville (MD): US Department of Health and Human Services, Public Health Service, National Center for Health Statistics. 1995. []. Accessed 27 July 2010.
3. Ross J,. Pelvic inflammatory disease. BMJ 2001; 322: 658 - 9.
4. Workowski KA, Berman SM,. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006; 55: 1 - 94.
5. Ross J, Judlin P, Nilas L,. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2007; 18: 662 - 6.
6. Morcos R, Frost N, Hnat M, Petrunak A, Caldito G,. Laparoscopic versus clinical diagnosis of acute pelvic inflammatory disease. J Reprod Med 1993; 38: 53 - 6.
7. Ross JDC, Cronje HS, Paszkowski T, Rakoczi I, Vildaite D, Kureishi A, etal. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double-blind, randomised trial. Sex Transm Infect 2006; 82: 446 - 51.
8. Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, etal. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100: 456 - 63.
9. Westrom LV,. Sexually transmitted diseases and infertility. Sex Transm Dis 1994; 21 (Suppl 2): S32 - 7.
10. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W Jr, Westrom L,. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503 - 9.
11. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, etal. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186: 929 - 37.
12. Ivey JB,. The adolescent with pelvic inflammatory disease: assessment and management. Nurse Pract 1997; 22: 78.
13. Bevan CD, Ridgway GL, Rothermel CD,. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31: 45 - 54.
14. Dunbar-Jacob J, Sereika SM, Foley SM, Bass NC, Ness RB,. Adherence to oral therapies in pelvic inflammatory disease. J Womens Health (Larchmt) 2004; 13: 285 - 91.
15. Haggerty CL, Ness RB,. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44: 953 - 60.
16. Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley A,. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. South Med J 1993; 86: 604 - 10.
17. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases. Treatment guidelines 2006. Updated recommendations April 2007. []. Accessed 27 July 2010.
18. Royal College of Obstetricians and Gynaecologists. Management of Acute Pelvic Inflammatory Disease. 2008; Green-top guideline No. 32. London: RCOG, 2008.
19. Heysteck M, Ross J, for the PID Study Group. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690 - 5.
20. Stass H, Dalhoff A, Kubitza D, Schhly U,. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060 - 5.
21. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, etal. Pharmacokinetics of a once-daily oral dose of moxifloxacin (BAY 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793 - 7.
22. Aldridge KE, Ashcraft DS,. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709 - 11.
23. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R,. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101 - 6.
24. Donati M, Rodriguez Fermepin M, Olmo A, DApote L, Cevenini R,. Comparative in vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother 1999; 43: 825 - 7.
25. Bébéar CM, De Barbeyrac B, Pereyre S, Renaudin H, Clerc M, Bébéar C,. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801 - 5.
26. Alexander C, Goldstein E, Citron D, DeCherney AH,. Review of the comparative in vitro susceptibility of female genital tract pathogens to older and newer fluoroquinolones. Anaerobe 2000; 6: 313 - 23.
27. Centers for Disease Control and Prevention. Update to CDCs sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007; 56: 332 - 6.
28. McCormack WM, Nowroozi K, Alpert S, Sackel SG, Lee YH, Lowe EW, etal. Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride. Sex Transm Dis 1977; 4: 125 - 31.
29. Heritier SR, Gebski VJ, Keech AC,. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 2003; 179: 438 - 44.
30. Hong S, Xin C, Qianhong Y, Yanan W, Wenyan X, Peeling RW, etal. Pelvic inflammatory disease in the Peoples Republic of China: aetiology and management. Int J STD AIDS 2002; 13: 568 - 72.
31. Wolner-Hanssen P, Paavonen J, Kiviat N, Young M, Eschenbach DA, Holmes KK,. Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline. Obstet Gynecol 1988; 71: 595 - 600.
32. Wendel GD Jr, Cox SM, Bauden RE, Theriot SK, Heard MC, Nobles BJ,. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am J Obstet Gynecol 1991; 164: 1390 - 6.
33. Kosseim M, Ronald A, Plummer FA, DCosta L, Brunham RC,. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam. Antimicrob Agents Chemother 1991; 35: 1651 - 6.
34. Centers for Disease Control and Prevention. Pelvic inflammatory disease: guidelines for prevention and management. MMWR Recomm Rep 1991; 40: 1 - 25.
35. Einwalter LA, Ritchie JM, Ault KA, Smith EM,. Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors. Perspect Sex Reprod Health 2005; 37: 135 - 40.
36. Trent M, Chung SE, Forrest L, Ellen JM,. Subsequently sexually transmitted infection after outpatient treatment of pelvic inflammatory disease. Arch Pediatr Adolesc Med 2008; 162: 1022 - 5.
37. Martin IM, Hoffmann S, Ison CA,. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother 2006; 58: 587 - 93.
38. Newman LM, Moran JS, Workowski KA,. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 (Suppl 3): S84 - 101.
39. Tapsall JW, Limnios EA, Bakar HM, Darussalam B, Ping YY, Buadromo EM, etal. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun Dis Intell 2008; 32: 48 - 51.
40. Jabeen K, Khan E, Hasan R,. Emergence of quinolone-resistant Neisseria gonorrhoeae in Pakistan. Int J STD AIDS 2006; 17: 30 - 3.
41. Sutrisna A, Soebjakto O, Wignall FS, Kaul S, Limnios EA, Ray S, etal. Increasing resistance to ciprofloxacin and other antibiotics in Neisseria gonorrhoeae from East Java and Papua, Indonesia, in 2004 - implications for treatment. Int J STD AIDS 2006; 17: 810 - 2.
42. Su X, Jiang F, Qimunge S, Dai X, Sun H, Ye S,. Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999-2006. Sex Transm Dis 2007; 34: 995 - 9.
43. Matsumoto T,. Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae. Int J Antimicrob Agents 2008; 31 (Suppl 1): S35 - 9.
44. Judlin P,. Current concepts in managing pelvic inflammatory disease. Curr Opin Infect Dis 2010; 23: 83 - 7.
45. Van Bambeke F, Tulkens PM,. Safety profile of the respiratory fluoroquinolone moxifloxacin. Comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359 - 78.
46. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R,. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940 - 50.